32882 Federal Register / Vol. 63, No. 115 /Tuesday, June 16, 1998 / Notices

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than July 1, 1998.

A. Federal Reserve Bank of New

York (Betsy Buttrill White, Senior Vice

President) 33 Liberty Street, New York,

New York 10045-0001:

1. J.P. Morgan & Co. Incorporated,

New York, New York (‘‘JPM’’), to engage

de novo through its subsidiaries,

including J.P. Morgan Investment

Management Inc., New York, New York,

in acting as a commodity pool operator

(‘‘CPO’’) for certain closed-end private

investment funds that are exempt from

registration under the Investment

Company Act of 1940 (15 U.S.C. § 80a1 et seq.). See Dresdner Bank AG, 84

Fed. Res. Bull. 361 (1998).

In connection with its proposal, JPM

also seeks to act as CPO for certain

open-end investment funds. JPM

submits that the funds will be managed

by an independent board that will be

responsible for the overall management

of the funds. JPM states that the

independent board, and not JPM, will

control the funds and will perform the

activities typically associated with being

a CPO. However, to avoid the

administrative burdens associated with

each individual board member having to

register as CPO, JPM will register as a

CPO itself.

In publishing this proposal for

comment, the Board does not take a

position on the issue raised by the

notice. Notice of the proposal is

published solely to seek the views of

interested parties on the issues

presented and does not represent a

determination by the Board that the

proposal meets, or is likely to meet, the

standards of the BHC Act.

Notificants’ proposal is available for

immediate inspection at the Federal

Reserve Bank of New York and the

offices of the Board in Washington, D.C.

Interested persons may express their

views on the proposal in writing,

including on whether the proposed

activities ‘‘can reasonably be expected

to produce benefits to the public, such

as greater convenience, increased

competition, or gains in efficiency, that

outweigh possible adverse effects, such

as undue concentration of resources,

decreased or unfair competition,

conflicts of interests, or unsound

banking practices.’’ 12 U.S.C. §

1843(c)(8).

Board of Governors of the Federal Reserve

System, June 11, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–16001 Filed 6–15–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 99011]

Notice of Availability of Funds;

Emerging Infections Program

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1999

funds for a cooperative agreement

program to establish an Emerging

Infections Program (EIP) to join a

national network of EIPs. This program

will assist in local, State, and national

efforts to conduct surveillance and

applied epidemiologic and laboratory

research in emerging infectious diseases

and to pilot and evaluate prevention

measures. This program addresses the

‘‘Healthy People 2000’’ priority area of

Immunization and Infectious Diseases.

The purpose of the program is to

assist State health departments to

establish new EIPs as part of the

national network. EIPs will be

population-based centers designed to

assess the public health impact of

emerging infections and to evaluate

methods for their prevention and

control.

Activities of the EIPs will fall into the

general categories of: (1) active

surveillance; (2) applied epidemiologic

and applied laboratory research; and (3)

implementation and evaluation of pilot

prevention/intervention projects.

The EIPs will maintain sufficient

flexibility to accommodate changes in

projects as required by the emergence of

public health infectious disease

problems. EIPs will be strategically

located to serve a variety of geographical

areas, diverse groups and difficult-toreach populations—e.g., under-served

women and children, the homeless,

immigrants and refugees, and persons

infected with HIV. They will enlist the

participation of local health

departments, academic institutions, and

other public and private organizations

with an interest in addressing public

health issues relating to emerging

infectious diseases, and will seek

support from sources, in addition to

CDC, to operate the EIP.

B. Eligible Applicants

Assistance will be provided only to

the health departments of States or their

bona fide agents, including the District

of Columbia, the Commonwealth of

Puerto Rico, the Virgin Islands, the

Commonwealth of the Northern Mariana

Islands, American Samoa, Guam,

federally-recognized Indian tribal

governments, the Federated States of

Micronesia, the Republic of the

Marshall Islands, and the Republic of

Palau. In consultation with States,

assistance may be provided to political

subdivisions of States.

The following States already

participating in the EIP cooperative

agreement program should not apply to

this announcement: California,

Connecticut, Georgia, Maryland,

Minnesota, New York, and Oregon.

C. Availability of Funds

Up to $1,000,000 is available in FY

1999 to fund two awards. The average

award will be about $500,000. This

amount is for both direct and indirect

costs. It is expected that the awards will

begin on or about October 1, 1998, and

will be made for a 12-month budget

period within a project period of up to

five years. The funding estimate may

change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

Note: Per instructions in Evaluation

Criteria section below, the application should

include proposals for four projects. CDC will

select from one to four of those projects to

fund based on the capacity of the applicant,

priorities of the EIP network, and availability

of resources.

Funding Preferences

EIPs are currently established in the

seven following states: California,

Connecticut, Georgia, Maryland,

Minnesota, New York, and Oregon. To

achieve appropriate geographical

representation in the EIP network, for

one of the two potential awards made

under this announcement, funding

preference may be given to approved

applications from States in Standard

Federal Regions VI, VII, and VIII.

Region VI: Arkansas, Louisiana, New

Mexico, Oklahoma, Texas

Region VII: Iowa, Kansas, Missouri,

Nebraska

Region VIII: Colorado, Montana, North

Dakota, South Dakota, Utah, Wyoming
Federal Register / Vol. 63, No. 115 /Tuesday, June 16, 1998 / Notices 32883

D. Program Requirements

Recipient Activities

1. Establish and operate an EIP to

further local, State, and national efforts

to address emerging infectious diseases:

a. Organize the EIP so that it will have

the capacity to conduct approximately

three concurrent projects.

b. Organize the EIP so that it will

maintain the ability to accommodate

changes in specific projects and

priorities as the public health system’s

need for information changes or new

health problems emerge.

c. Operate the EIP so that it can

function effectively as part of a national

network of EIPs. Collaborate with CDC

and other EIP sites, through the EIP

steering committee and otherwise, to

coordinate project priorities and to

assure that important emerging

infections issues are addressed

appropriately.

d. Establish the EIP in a defined

population, which could include either

an entire State or a geographically

defined area (or areas) within a State. To

accomplish the objectives of certain EIP

activities, a minimum population base

of approximately 1,000,000 may be

necessary.

2. Obtain technical and financial

assistance to supplement the core

assistance from CDC.

3. Collaborate with other public and

private organizations that have an

interest in addressing public health

issues relating to emerging infectious

diseases (e.g., local public health

agencies, schools of public health,

university medical schools, medical

examiners, health care providers,

clinical laboratories, community-based

organizations, other Federal and State

government agencies, research

organizations, medical institutions,

foundations, etc.).

4. Propose and conduct emerging

infections activities in collaboration

with appropriate partner organizations.

Collaborate with other EIPs, as

appropriate, to finalize protocols for and

conduct EIP activities.

a. Categories of EIP activities.

Activities of the EIP will fall into three

categories:

(1) Active population-based

surveillance projects. These may

include collection and submission of

disease-causing infectious agents to

State, CDC, or other laboratories. For

example, the surveillance case

definition for the condition might

involve detection of a positive culture or

a drug resistant isolate in a microbiology

laboratory, a serologic test result, a

histopathologic finding, or a clinical

syndrome, depending upon the disease

or condition under surveillance; the

specific approach to surveillance could

also vary depending on the disease or

condition under surveillance.

Surveillance should be comprehensive

(e.g., inclusion of audits to assure

complete reporting), with active rather

than passive case-finding.

(2) Applied epidemiologic and

applied laboratory projects. Examples of

potential projects include: evaluation of

illnesses often not specifically

diagnosed for which information about

trends and etiology are important (e.g.,

diarrhea, community-acquired

pneumonia); evaluation of clinical

outcomes or risk factors for drug

resistant infections; and evaluation of

the clinical spectrum of influenza and

the efficacy of influenza vaccines in

target populations.

(3) Implementation and evaluation of

pilot prevention/intervention projects

for emerging infectious diseases.

Examples might include assessment of

efforts to promote safe food preparation

in the home, evaluation of impact of

hand-washing promotion on infectious

diseases in child-care facilities, or

evaluation of antibiotic prescribing

practices in out-patient settings.

b. Specific EIP activities. In the

application, propose a total of 4 projects

from the following list (see Applicant

Content section for details):

Required (propose both):

(1) Active population-based

laboratory surveillance for foodborne

diseases and related activities

(FoodNet).

(2) Active Bacterial Core Surveillance

(ABCs) activities.

Optional (select and propose 2 of the

following):

(3) Active surveillance for syndromes

of possibly infectious etiology (e.g.,

encephalitis, fulminant hepatitis).

(4) A collaboration with one or more

managed-care organizations on a

surveillance, risk factor, or pilot

prevention project.

(5) A project to quantify or otherwise

explore linkages between chronic and

infectious diseases.

5. As a part of certain EIP projects,

provide specimens such as diseasecausing isolates or serum specimens to

appropriate organizations (which may

include CDC) for laboratory evaluation

(e.g., molecular epidemiologic studies,

evaluation of diagnostic tools).

6. Manage, analyze, and interpret data

from EIP projects, and publish and

disseminate important public health

information stemming from EIP projects

in collaboration with CDC.

7. Monitor and evaluate scientific and

operational accomplishments and

progress in achieving the purpose of this

program.

8. Provide training opportunities at

the EIP site (e.g., infectious disease

fellows, laboratory fellows, public

health students) that are consistent with

the purpose of this announcement.

CDC Activities

1. Provide consultation, scientific,

and technical assistance in general

operation of the EIP and in designing

and conducting individual EIP projects.

2. Participate in analysis and

interpretation of data from EIP projects.

Participate in the dissemination of

findings and information stemming

from EIP projects.

3. Assist in monitoring and evaluating

scientific and operational

accomplishments of the EIP and

progress in achieving the purpose and

overall goals of this program.

4. As needed, perform laboratory

evaluation of specimens or isolates (e.g.,

molecular epidemiologic studies,

evaluation of diagnostic tools) obtained

in EIP projects and integrate results with

other data from EIP projects.

E. Application Content

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections to develop

the application. Your application will

be evaluated on the criteria listed, so it

is important to follow them in preparing

your program plan.

Applications should address the

following topics in the order presented:

1. Understanding the objectives of the

EIP;

2. Description of the population base

for the EIP;

3. Description of existing capacity to

assess, control, and prevent emerging

infectious diseases;

4. Operational plan (including 4

project proposals as described below);

5. Personnel qualifications and

management plan;

6. Evaluation plan; and

7. Budget.

Applicants should propose a total of

4 projects from the following list of

activities.

Note: Two of the four projects proposed

must be the FoodNet and ABC’s projects

(numbers 1 and 2 below). The other two

should be selected from numbers 3–5 below.

Each specific project proposal should be

clearly identified in a distinct portion of the

Operational Plan and should not exceed 3

pages. Though the activities described below

address distinct issues and needs, they may

be implemented in an integrated manner

such that staff members work on more than

one activity (supplies and equipment are

shared, etc.):
32884 Federal Register / Vol. 63, No. 115 /Tuesday, June 16, 1998 / Notices

1. Population-based laboratory

surveillance for foodborne diseases and

related activities (FoodNet): Conduct

population-based laboratory

surveillance including completion of

case reports (which include

demographic information as well as

information about the diagnosis and

outcome) and collection of diseasecausing isolates—for seven bacterial and

two parasitic foodborne pathogens

(Salmonella, E. coli O157,

Campylobacter, Shigella, Listeria,

Yersinia, Vibrio, Cryptosporidium and

Cyclospora). Completeness of

surveillance should be verified by

periodic (at least yearly) audits of area

laboratories. In these audits, records in

each laboratory should be reviewed and

case report form information should be

completed on cases not identified

through the routine surveillance. Since

this core activity will be done in

collaboration with other EIP sites and

CDC, the project should be designed so

that data can be integrated with data

from the other EIPs. Additional core

activities for foodborne disease

surveillance: (a) systematic survey of

physician and laboratory practices

regarding diagnostic practices for

diarrheal pathogens (similar to those

done in other sites), (b) active hemolytic

uremic syndrome (HUS) surveillance

through pediatric nephrologists, (c)

pulsed-field gel electrophoresis (PFGE)

of all E. coli O157 from catchment area,

as part of expanding national network,

and when the method is ready to be

applied, PFGE of Salmonella

typhimurium isolates, (d) participation

in national antimicrobial resistance

surveillance, and (e) surveillance for

outbreaks of calicivirus gastroenteritis

and/or endemic calicivirus

gastroenteritis.

2. Active Bacterial Core Surveillance

(ABCs) activities: Population-based

laboratory surveillance for invasive

disease caused by emerging, vaccine

preventable, and drug resistant bacterial

diseases. Conduct active populationbased laboratory surveillance including

completion of case reports (which

include demographic information as

well as information about the diagnosis

and outcome) and collection of diseasecausing isolates for invasive bacterial

disease caused by Streptococcus

pneumoniae, Haemophilus influenzae,

Neisseria meningitidis, groups A and B

streptococci, Vancomycin-resistant

enterococcus and Listeria

monocytogenes. Collect additional

demographic, medical, and vaccination

history information on all invasive

Haemophilus influenzae cases in

persons less than 15 years of age (very

small numbers). Collect additional

information in cases of early-onset

group B streptococcus disease.

Completeness of surveillance should be

verified by periodic (semiannual) audits

of area laboratories. In these audits,

records in each laboratory should be

reviewed and case report form

information should be completed on

cases not identified through the routine

surveillance. Since this core activity

will be done in collaboration with the

other EIP sites and CDC, the project

should be designed so that data can be

integrated with data from the other EIPs.

3. Active surveillance for syndromes

of possibly infectious etiology: (For

example: encephalitis, fulminant

hepatitis, or myocarditis.) Protocols for

this project should be developed

together with CDC and the EIP sites

involved in the current EIP project on

Unexplained Deaths and Critical

Illnesses Possibly Due to Infections.

4. Collaboration with managed-care

organizations. (For example,

collaborations with one or more

managed-care organizations might

include surveillance of infectious

syndromes or piloting and evaluation of

prevention projects.) Emphasis should

be on infectious diseases of public

health importance.

5. Linkages between chronic and

infectious diseases. (For example,

projects might seek to quantify or

otherwise explore links between chronic

diseases and infectious diseases (e.g.,

hepatitis C and chronic liver disease;

infections due to Chlamydia

pneumoniae and atherosclerosis;

mycoplasma infections and asthma,

human papilloma virus and cervical

cancer, genital infections and premature

birth, or others.)

Funding in future years may permit

implementation of projects which are

developed and implemented by

individual EIP sites. Briefly describe

activities which the applicant would

propose to implement in the EIP in the

future if given the opportunity.

Page Limitations

The application narrative (excluding

budget, appendices, and required forms)

must not exceed 25 single-spaced pages,

printed on one side, with one inch

margins, and unreduced font. Only the

following information should be

presented in appendices: Letters of

support, documentation of bona fide

agent status, curricula vitaes, and

budget. All other materials or

information that should be included in

the narrative will not be accepted if

placed in the appendices.

Budget Instructions

For each line-item (as identified on

the Form 424a of the application), show

both Federal and non-Federal (e.g., State

funding) shares of total cost for the EIP.

For each staff member listed under the

Personnel line item, indicate their

specific responsibilities relative to each

of the proposed projects. Include

provisions for travel of the principal

investigator and one EIP participant to

two meetings at CDC in Atlanta during

the first year of the program.

Bona Fide Agent Status

If applicant is an agent of a State

public health agency and not a State

public health agency itself,

documentation that applicant is acting

as a bona fide agent of a State public

health agency should be provided in an

appendix. Applicants acting as bona

fide agents of a State public health

agency are strongly encouraged to

consult with CDC’s Grants Management

Specialist (identified in Section J below)

prior to submitting the application for

guidance regarding what constitutes

acceptable documentation.

F. Submission and Deadline

Notice of Intent To Apply

In order to assist CDC in planning and

executing the evaluation of applications

submitted under this announcement, all

parties intending to submit an

application are requested to inform CDC

of their intention to do so at least ten

(10) days prior to the application due

date. Notification should include: (1)

name and address of institution, and (2)

name, address, and telephone number of

contact person. Notification should be

provided by facsimile, postal mail, or Email, to Laura Conn, National Center for

Infectious Diseases (NCID), Centers for

Disease Control and Prevention (CDC),

1600 Clifton Road, NE., Mailstop C–12,

Atlanta, GA 30333, E-mail address

lbk1@cdc.gov, Facsimile (404) 639–

4197.

Application

Submit the original and two copies of

PHS 5161–1 (OMB Number 0937–0189).

Forms are provided in the application

kit. On or before July 31, 1998, submit

the application to: Oppie Byrd, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Announcement 99011,

Centers for Disease Control and

Prevention (CDC), 255 East Paces Ferry

Road, NE., Room 300, Mailstop E–18,

Atlanta, GA 30305–2209

If your application does not arrive in

time for submission to the independent

review group, it will not be considered
Federal Register / Vol. 63, No. 115 /Tuesday, June 16, 1998 / Notices 32885

in the current competition unless you

can provide proof that you mailed it on

or before the deadline (i.e., receipt from

U.S. Postal Service or a commercial

carrier; private metered postmarks are

not acceptable).

G. Evaluation Criteria

Each application will be evaluated

individually against the following

criteria by an independent review group

appointed by CDC. Your application

should address each section in the order

presented below:

1. Understanding the objectives of the

EIP (10 points)

a. Demonstration of a clear

understanding of the background and

objectives of this cooperative agreement

program.

b. Demonstration of a clear

understanding of the requirements,

responsibilities, problems, constraints,

and complexities that may be

encountered in establishing and

operating the EIP.

c. Demonstration of a clear

understanding of the roles and

responsibilities of participation in the

EIP network.

2. Description of the population base

of the EIP area (10 points).

a. Clear definition of the geographic

area and population base in which the

EIP will operate. Detailed description of

the demographics of the proposed

population base.

b. Clear description of various special

populations within the defined

population base as they relate to the

proposed activities of the EIP, such as

the rural or inner city poor, under

served women and children, the

homeless, immigrants and refugees, and

persons infected with HIV.

c. Extent to which the population base

is diverse in terms of demographics and

special populations.

3. Description of existing capacity to

assess, control and prevent emerging

infectious diseases: (35 points)

a. Description of applicant’s past

experience in conducting active

surveillance, applied epidemiologic

research, applied laboratory research,

and prevention research, in general, and

on emerging infectious diseases,

including antimicrobial drug resistant,

foodborne and waterborne, currently or

potentially vaccine preventable, and

opportunistic diseases.

b. Demonstration of applicant’s ability

to develop and maintain strong

cooperative relationships with both

public and private, local and regional,

medical, public health, laboratory,

academic, and community

organizations. Evidence of applicant’s

ability to solicit and secure

programmatic collaboration, and

financial and technical support from

such organizations.

c. Demonstration of support from nonapplicant participating agencies,

institutions, organizations, laboratories,

individuals, consultants, etc., indicated

in applicant’s operational plan.

Applicant should provide (in an

appendix) letters of support which

clearly indicate collaborators’

willingness to be participants in the EIP.

Do not include letters of support from

CDC personnel.

4. Operational plan (40 points).

a. The extent to which the applicant’s

plan for establishing and operating the

population-based EIP clearly describes

the proposed organizational and

operating structure/procedures and

clearly identifies the roles and

responsibilities of all participating

agencies, organizations, institutions,

and individuals. The extent to which

the applicant describes plans for

collaboration with CDC and other EIP

sites in the establishment and operation

of the EIP and individual EIP projects,

including project design/development

(e.g., protocols), management and

analysis of data, and synthesis and

dissemination of findings.

b. Description of applicant’s

partnerships with necessary and

appropriate organizations for

establishing and operating the proposed

EIP and for conducting individual EIP

projects.

c. Description of plans to provide

training opportunities for providers-intraining (e.g., infectious disease fellows,

laboratory fellows, public health

students).

d. Description of a plan to solicit and

secure financial and technical assistance

from other public and private

organizations (e.g., schools of public

health, university medical schools,

public health laboratories, communitybased organizations, other Federal and

State government agencies, research

organizations, foundations, etc.) to

supplement the core funding from CDC.

e. Quality of the proposed projects (as

requested in the Application Content

section above) regarding consistency

with public health needs, intent of this

program, feasibility, methodology/

approach, and collaboration/

participation of partner organizations.

The degree to which the applicant has

met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes: (1)

The proposed plan for the inclusion of

both sexes and racial and ethnic

minority populations for appropriate

representation; (2) The proposed

justification when representation is

limited or absent; (3) A statement as to

whether the design of the study is

adequate to measure differences when

warranted; and (4) A statement as to

whether the plans for recruitment and

outreach for study participants include

the process of establishing partnerships

with community(ies) and recognition of

mutual benefits.

5. Personnel qualifications and

management plan.

a. Identification of applicant’s key

professional personnel to be assigned to

the EIP and EIP projects (provide

curriculum vitae for each in an

appendix). Clear identification of their

respective roles in the management and

operation of the EIP. Descriptions of

their experience in conducting work

similar to that proposed in this

announcement.

b. Identification of key professional

personnel from other participating or

collaborating institutions, agencies,

organizations outside of the applicant’s

agency that will be assigned to EIP

activities (provide curriculum vitae for

each in an appendix). Clear

identification of their respective roles.

c. Description of all support staff and

services to be assigned to the EIP.

d. Description of approach to

maintaining sufficiently flexible EIP

staffing to accommodate the likelihood

that the requirements of EIP projects

will change from time to time due to

changes in the public health system’s

need for information or the emergence

of new diseases.

6. Evaluation (5 points).

a. Quality of plan for monitoring and

evaluating scientific and operational

accomplishments of the EIP and of

individual EIP projects.

b. Quality of plan for monitoring and

evaluating progress in achieving the

purpose and overall goals of this

cooperative agreement program.

7. Budget (not scored).

Extent to which the line-item budget

is detailed, clearly justified, and

consistent with the purpose and

objectives of this program. Extent to

which applicant shows both Federal

and non-Federal (e.g., State funding)

shares of total cost for the EIP.

If requesting funds for any contracts,

provide the following information for

each proposed contract: (1) Name of

proposed contractor, (2) breakdown and

justification for estimated costs, (3)

description and scope of activities to be

performed by contractor, (4) period of

performance, and (5) method of

contractor selection (e.g., sole-source or

competitive solicitation).

8. Human Subjects (not scored).
32886 Federal Register / Vol. 63, No. 115 /Tuesday, June 16, 1998 / Notices

Does the application adequately

address the requirements of Title 45

CFR Part 46 for the protection of human

subjects?

ll Yes ll No

Comments:lllll

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two

copies of:

1. Semiannual progress reports. The

first semiannual report is required with

each year’s continuation application

and should cover program activities

from beginning of the current budget

period to date of report/application

preparation. The second semiannual

report is due 90 days after the end of

each budget period and should cover

activities for the entire budget period

recently completed. This second report

may simply be a ‘‘cut/paste’’ update of

the first semiannual (partial budget

period) report to add information from

date of first report to the end of the

budget period.

2. Financial Status Report (FSR), no

more than 90 days after the end of the

budget period; and

3. Final FSR and performance reports,

no more than 90 days after the end of

the project period. Send all reports to:

Oppie Byrd, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), 255 East Paces Ferry Rd., NE.,

Rm. 300, Mailstop E–18, Atlanta, GA

30305–2209.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I in the

application kit.

AR98–1 Human Subjects Requirements

AR98–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR98–7 Executive Order 12372 Review

AR98–9 Paperwork Reduction Act

Requirements

AR98–10 Smoke-Free Workplace

Requirements

AR98–11 Healthy People 2000

AR98–12 Lobbying Restrictions

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

Sections 301(a) and 317(k)(1)(2) of the

Public Health Service Act [42 U.S.C.

sections 241(a) and 247b(k)(1)(2)], as

amended. The Catalog of Federal

Domestic Assistance number is 93.283.

J. Where To Obtain Additional

Information

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888–472–6874). You will be asked to

leave your name and address and will

be instructed to identify the

Announcement number of interest.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from Oppie

Byrd, Grants Management Specialist

Grants Management Branch,

Procurement and Grants Office,

Announcement 99011, Centers for

Disease Control and Prevention (CDC),

255 East Paces Ferry Road, NE., Room

300, Mailstop E–18, Atlanta, GA 30305–

2209, Telephone (404) 842–6546, E-mail

address: oxb3@cdc.gov.

For program technical assistance,

contact Robert W. Pinner, M.D., or Pat

McConnon, M.P.H., Office of the

Director, National Center for Infectious

Diseases, Centers for Disease Control

and Prevention (CDC), Mailstop C–12,

1600 Clifton Road, NE., Atlanta, GA

30333, Telephone (404) 639–2603, Email address for Dr. Pinner:

rwp1@cdc.gov/E-mail address for Mr.

McConnon: pjm2@cdc.gov.

See also the CDC homepage on the

Internet: http://www.cdc.gov

Potential applicants may obtain a

copy of ‘‘Addressing Emerging

Infectious Disease Threats: A Prevention

Strategy for the United States’’ through

the Centers for Disease Control and

Prevention (CDC), National Center for

Infectious Diseases, Office of Planning

and Health Communication—EP,

Mailstop C–14, 1600 Clifton Road, NE.,

Atlanta, GA 30333. Requests may also

be sent by facsimile to (404) 639–3039.

Dated: June 10, 1998.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 98–15924 Filed 6–15–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Disease, Disability, and Injury

Prevention and Control Special

Emphasis Panel (SEP): Cooperative

Agreements for Prevention Research

Centers, Program Announcement

98047; Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Disease, Disability, and Injury

Prevention and Control SEP: Cooperative

Agreements for Prevention Research Centers,

Program Announcement 98047.

Times and Dates: 8 a.m.–5 p.m., July 14,

1998; 8 a.m.–5 p.m., July 15, 1998; 8 a.m.–

5 p.m., July 16, 1998.

Place: Sheraton Colony Square Hotel, 188

14th Street, N.E., Atlanta, Georgia 30316.

Status: The meeting will be open from 8

a.m.–9 a.m., July 14, 1998; and closed 9 a.m.

July 14, 1998, through 5 p.m. July 16, 1998.

Matters to be Discussed: The meeting will

include the review, discussion, and

evaluation of applications received in

response to Program Announcement 98047.

Portions of this meeting will be closed to

the public in accordance with provisions set

forth in section 552b(c)(4) and (6), Title 5

U.S.C., and the Determination of the

Associate Director for Management and

Operations, CDC, pursuant to Pub. L. 92–463.

Contact Person for more Information:

Michael N. Waller, National Center for

Chronic Disease Prevention and Health

Promotion, CDC, M/S K30, 4770 Buford

Highway, N.E., Atlanta, Georgia 30345,

telephone 770/488–5264.

Dated: June 10, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 98–15926 Filed 6–15–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Office of the Director, Centers for

Disease Control and Prevention (CDC);

Meeting

Name: Guide to Community Preventive

Services (GCPS) Task Force Meeting.

Times and Dates: 10 a.m.–5 p.m., June 22,

1998; 8 a.m.–3 p.m., June 23, 1998.

Place: The Wyndham Garden Hotel, 3340

Peachtree Road, NE, Atlanta, Georgia 30326,

telephone (404) 231–1234.